2200 Pennsylvania Avenue, NW
District of Columbia
We are a science and technology innovator committed to helping our customers solve complex challenges, and improving quality of life around the world.
A global family of more than 20 operating companies, we drive meaningful innovation in some of today’s most dynamic, growing industries. With operating companies based around the world—from California to Copenhagen—our groundbreaking businesses transform the fields of diagnostics, life sciences, dental care, and environmental and applied solutions by:
• improving patient health through powerful tools that increase diagnostic confidence
• advancing scientific research to illuminate the causes of disease and pave the way to new, life-saving treatments
• improving dental outcomes and patient care around the world
• ensuring the freshness, dosages and safety of food, pharmaceuticals and consumer goods
• protecting our global water supply and promoting environmental stewardship
We are a team of 59,000 dedicated associates who are Helping Realize Life’s Potential every day by bringing our diverse skills, backgrounds, and perspectives together to make a difference.
We are a diverse team of people and operating companies, each with unique missions and challenges. Yet, we are united by Our Shared Purpose, which directs how we live out every day to achieve our most ambitious goals.
Our Shared Purpose confirms our commitment to helping our customers achieve amazing things and the high standards by which we measure our own success. We innovate forward-looking technologies to solve our customers’ most complex challenges. We are their agents of possibility.
96 articles with Danaher
Danaher Corporation announced that its wholly owned subsidiary, DH Europe Finance II S.à r.l., has priced an offering
Danaher Corporation announced results for the third quarter 2019.
Proposed transaction to include label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses
Envista Holdings Corporation, a subsidiary of Danaher Corporation, announced the pricing of its initial public offering of 26,768,000 shares of its common stock at a price to the public of $22.00 per share.
Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.17 per share of its common stock, payable on October 25, 2019 to holders of record on September 27, 2019.
The incidence of drug-induced liver injuries is increasing at a significant rate across the world.
Danaher Corporation announced results for the second quarter 2019.
Danaher Corporation announced that Envista Holdings Corporation will be the name of the separate company Danaher intends to create and take public via an initial public offering in the second half of 2019.
Danaher Corporation announced that it will webcast its quarterly earnings conference call for the second quarter 2019 on Thursday, July 18, 2019 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, and Executive Vice President, Rainer Blair, will be presenting at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada on Wednesday, May 15, 2019 at 8:00 a.m. PT.
Danaher Corporation announced results for the first quarter 2019.
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering - March 1, 2019
Danaher Corporation announced that it has closed concurrent offerings of 12,100,000 shares of common stock at a price to the public of $123.00 per share and 1,650,000 shares of 4.75% Series A Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
Danaher Corporation announced that it has priced concurrent offerings of 11,000,000 shares of common stock at a price to the public of $123.00 per share and 1,500,000 shares of 4.75% Series A Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.
GE announced a definitive agreement to sell its BioPharma business to Danaher Corporation for a total consideration of $21.4 billion, including $21 billion in cash as well as Danaher’s assumption of certain pension liabilities.
Danaher Corporation announced that it has entered into a definitive agreement with General Electric Company to acquire the Biopharma business of GE Life Sciences for a cash purchase price of approximately $21.4 billion.
Shares of General Electric jumped as much as 13 percent in trading this morning after Danaher Corporation announced it was acquiring the conglomerate’s biopharma business, GE Biopharma, for $21.4 billion.
Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on the Company's fourth quarter 2018 performance in a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California at 8:00 a.m. PT.
Danaher Corporation announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 8, 2019 at 8:00 a.m. PT.
Ahead of its annual investor and analyst meeting to be held in New York City, Danaher Corporation initiated its 2019 outlook.
Danaher Corporation announced today that its Board of Directors has approved a regular quarterly dividend of $0.16 per share payable on January 25, 2019 to holders of record on December 28, 2018.